Alkermes plc - Ordinary Shares (ALKS)
31.09
+0.00 (0.00%)
NASDAQ · Last Trade: Oct 23rd, 4:12 AM EDT
Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicine. Jazz litigation settled.
Via Benzinga · October 22, 2025
DUBLIN, IRELAND – October 22, 2025 – Avadel Pharmaceuticals (NASDAQ: AVDL) shareholders are celebrating today as Alkermes plc (NASDAQ: ALKS) announced a definitive agreement to acquire the company for a staggering $2.1 billion. The news sent Avadel's stock price soaring in premarket trading, reflecting a significant premium offered to its investors.
Via MarketMinute · October 22, 2025
The companies are both working in the sleep space, focusing on excessive daytime sleepiness.
Via Investor's Business Daily · October 22, 2025
Alkermes will buy Avadel for up to $20 per share.
Via Stocktwits · October 22, 2025

Via Benzinga · May 28, 2025
Analysts' ratings for Alkermes (NASDAQ: ALKS) over the last quarter vary from bullish to bearish, as provided by 9 analysts. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
Via Benzinga · September 26, 2025
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Via Benzinga · September 26, 2025
Via Benzinga · September 3, 2025
Via Benzinga · September 3, 2025
Via Benzinga · September 3, 2025
Via Benzinga · September 3, 2025
ALKERMES PLC (ALKS) is a strong value stock with low P/E ratios, high profitability, and a debt-free balance sheet, making it an attractive pick for long-term investors.
Via Chartmill · August 5, 2025
Alkermes PLC (ALKS) reported strong Q2 2025 results, beating revenue and EPS estimates, driving a 7.8% pre-market rally. The company reaffirmed full-year guidance, signaling confidence in growth.
Via Chartmill · July 29, 2025
All four companies are testing out orexin agonists to improve the symptoms of narcolpesy.
Via Investor's Business Daily · July 21, 2025
Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability across all doses.
Via Benzinga · July 21, 2025
The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.
Via Stocktwits · July 7, 2025
ALKERMES PLC (NASDAQ:ALKS) shows strong profitability and financial health while trading at a discount to peers, making it a potential value opportunity in biopharma.
Via Chartmill · July 4, 2025
Via Benzinga · June 17, 2025
Via Benzinga · June 17, 2025